Targeting of the TSHR with K1-70TM may provide new therapeutic strategies for the management of patients with Graves’ disease, patients with Graves’ ophthalmopathy, patients with thyroid cancer and other patients who would benefit from controlling TSHR activity [10–15]. This evidence concerns the gene TSHR and thyroid gland carcinoma.